alexa Rectal transmission of transmitted founder HIV-1 is efficiently prevented by topical 1\% tenofovir in BLT humanized mice.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Chateau ML, Denton PW, Swanson MD, McGowan I, Garcia JV, Chateau ML, Denton PW, Swanson MD, McGowan I, Garcia JV

Abstract Share this page

Abstract Rectal microbicides are being developed to prevent new HIV infections in both men and women. We focused our in vivo preclinical efficacy study on rectally-applied tenofovir. BLT humanized mice (n = 43) were rectally inoculated with either the primary isolate HIV-1JRCSF or the MSM-derived transmitted/founder (T/F) virus HIV-1THRO within 30 minutes following treatment with topical 1\% tenofovir or vehicle. Under our experimental conditions, in the absence of drug treatment we observed 50\% and 60\% rectal transmission by HIV-1JRCSF and HIV-1THRO, respectively. Topical tenofovir reduced rectal transmission to 8\% (1/12; log rank p = 0.03) for HIV-1JRCSF and 0\% (0/6; log rank p = 0.02) for HIV-1THRO. This is the first demonstration that any human T/F HIV-1 rectally infects humanized mice and that transmission of the T/F virus can be efficiently blocked by rectally applied 1\% tenofovir. These results obtained in BLT mice, along with recent ex vivo, Phase 1 trial and non-human primate reports, provide a critically important step forward in the development of tenofovir-based rectal microbicides.
This article was published in PLoS One and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords